OncoMatch

OncoMatch/Clinical Trials/NCT05053854

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Is NCT05053854 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Talazoparib for neuroendocrine tumors.

Phase 1RecruitingPeter MacCallum Cancer Centre, AustraliaNCT05053854Data as of May 2026

Treatment: Talazoparib — This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: peptide receptor radionuclide therapy (177Lu, 111In, 90Y)

Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled)

Cannot have received: PARP inhibitor

Any prior exposure to ... PARPi

Cannot have received: immunotherapy

Any prior exposure to ... immunotherapy

Cannot have received: systemic therapy

Exception: except short acting SSA

another systemic therapy administered in the last 3 weeks (except short acting SSA)

Cannot have received: surgery

Surgery ... within <3 weeks of registration

Cannot have received: radiotherapy

radiotherapy within <3 weeks of registration

Lab requirements

Blood counts

Haemoglobin ≥100 g/L; Absolute neutrophil count ≥1.5x10^9/L; Platelets ≥150 x10^9/L

Kidney function

eGFR ≥ 50 ml/min

Liver function

Total bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN if no liver metastasis or ≤5 x ULN with liver metastases; Albumin ≥ 30 g/L

adequate bone marrow, hepatic and renal function defined as: Haemoglobin ≥100 g/L; Absolute neutrophil count ≥1.5x109/L; Platelets ≥150 x109/L; Total bilirubin ≤1.5 x ULN; AST/ALT ≤2.5 x ULN if no liver metastasis or ≤5 x ULN with liver metastases; Albumin ≥ 30 g/L; eGFR ≥ 50 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify